What Did Big Pharma Earnings Say About China Growth?
This article was originally published in PharmAsia News
Moving from a mixed to a more pessimistic outlook, top executives at multinational drug firms see China as fast losing its shine, despite the country continuing to lead growth in the emerging markets. PharmAsia News has combed through quarterly earnings reports to bring you the winners, laggards and most successful growth strategies in this increasingly challenging market.
You may also be interested in...
Slowing growth in China, particularly in some consumer sectors, has prompted words of caution from Abbott over the outlook for the remainder of the year, although its CEO remains positive on this key emerging market.
Two new sets of data on growth in China’s turbulent pharma sector paint a mixed and complex picture, indicating both challenges and opportunities ahead for multinational and domestic firms in the country.
Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.